- Home
- HAVA vs ANIK Comparison
HAVA vs ANIK Comparison
Compare HAVA & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAVA | ANIK |
|---|---|---|
| Founded | 2024 | 1983 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.0M | 200.9M |
| IPO Year | 2025 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HAVA | ANIK |
|---|---|---|
| Price | $10.19 | $21.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 44.5K | ★ 120.6K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $112,819,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.90 | $8.56 |
| 52 Week High | $10.19 | $22.88 |
Technical Indicators
Market Signals| Indicator | HAVA | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 62.80 |
| Support Level | $9.98 | $14.13 |
| Resistance Level | N/A | $22.88 |
| Average True Range (ATR) | 0.01 | 1.19 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 100.00 | 61.08 |
Price Performance
Historical ComparisonAbout HAVA Harvard Ave Acquisition Corporation Class A Ordinary Share
Harvard Ave Acquisition Corp is a blank check company.
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.